Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$122.81
4.964.21%
al cierre: -
$122.99
0.180.15%
After hour: Oct 17, 7:49 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Gilead Sciences Inc ha un obiettivo di prezzo di consenso pari a $110.36, stabilito in base alle ultime valutazioni degli analisti di 29. Le ultime 3 valutazioni degli analisti sono state rilasciate da Citigroup, JP Morgan y RBC Capital il octubre 8, 2025, septiembre 16, 2025 y agosto 8, 2025. Con un obiettivo di prezzo medio di $126 tra le Citigroup, JP Morgan y RBC Capital, c'è un implicito 2.45% upside per Gilead Sciences Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Citigroup
JP Morgan
RBC Capital
UBS
Truist Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Gilead Sciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/08/2025 | 9.77% | Citigroup | $125 → $135 | Maintains | Buy | |||
09/16/2025 | 17.9% | JP Morgan | $135 → $145 | Maintains | Overweight | |||
08/08/2025 | -20.32% | RBC Capital | $96 → $98 | Maintains | Sector Perform | |||
08/08/2025 | -8.94% | UBS | $108 → $112 | Maintains | Neutral | |||
08/08/2025 | 3.26% | Truist Securities | $108 → $127 | Upgrade | Hold → Buy | |||
07/25/2025 | 8.14% | Needham | → $133 | Upgrade | Hold → Buy | |||
05/21/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
05/05/2025 | -4.87% | Mizuho | $100 → $117 | Maintains | Outperform | |||
04/25/2025 | 1.63% | Oppenheimer | $132 → $125 | Maintains | Outperform | |||
04/25/2025 | 9.77% | Morgan Stanley | $130 → $135 | Maintains | Overweight | |||
04/25/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/22/2025 | 1.63% | Cantor Fitzgerald | → $125 | Assumes | → Overweight | |||
04/17/2025 | -2.43% | BMO Capital | $115 → $120 | Maintains | Outperform | |||
03/27/2025 | 5.7% | JP Morgan | $120 → $130 | Maintains | Overweight | |||
03/11/2025 | 5.7% | Morgan Stanley | $123 → $130 | Maintains | Overweight | |||
03/05/2025 | 2.45% | B of A Securities | $116 → $126 | Maintains | Buy | |||
03/05/2025 | 13.83% | Wells Fargo | $120 → $140 | Maintains | Overweight | |||
03/04/2025 | 7.33% | Oppenheimer | $115 → $132 | Maintains | Outperform | |||
02/18/2025 | -2.43% | Deutsche Bank | $80 → $120 | Upgrade | Hold → Buy | |||
02/13/2025 | -5.68% | B of A Securities | $109 → $116 | Maintains | Buy | |||
02/12/2025 | -2.43% | JP Morgan | $115 → $120 | Maintains | Overweight | |||
02/12/2025 | -18.69% | Baird | $95 → $100 | Maintains | Neutral | |||
02/12/2025 | -26.82% | RBC Capital | $84 → $90 | Maintains | Sector Perform | |||
02/12/2025 | -21.94% | Goldman Sachs | $85 → $96 | Maintains | Neutral | |||
02/12/2025 | -6.5% | BMO Capital | $110 → $115 | Maintains | Outperform | |||
02/12/2025 | -2.43% | Wells Fargo | $105 → $120 | Maintains | Overweight | |||
02/12/2025 | -10.56% | Piper Sandler | $105 → $110 | Maintains | Overweight | |||
02/12/2025 | 0.01% | Morgan Stanley | $113 → $123 | Maintains | Overweight | |||
02/12/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/03/2025 | -31.7% | RBC Capital | $84 → $84 | Reiterates | Sector Perform → Sector Perform | |||
01/29/2025 | -10.56% | BMO Capital | $102 → $110 | Maintains | Outperform | |||
01/29/2025 | -6.5% | JP Morgan | $105 → $115 | Maintains | Overweight | |||
01/10/2025 | -8.12% | Morgan Stanley | $87 → $113 | Upgrade | Equal-Weight → Overweight | |||
12/11/2024 | -34.95% | Cantor Fitzgerald | $80 → $80 | Reiterates | Neutral → Neutral | |||
12/11/2024 | -31.7% | RBC Capital | $84 → $84 | Reiterates | Sector Perform → Sector Perform | |||
12/10/2024 | -6.5% | Oppenheimer | $105 → $115 | Reiterates | Outperform → Outperform | |||
12/10/2024 | -11.37% | B of A Securities | → $109 | Reinstates | → Buy | |||
11/21/2024 | -21.94% | UBS | $70 → $96 | Maintains | Neutral | |||
11/21/2024 | -18.69% | Mizuho | $90 → $100 | Maintains | Outperform | |||
11/18/2024 | -31.7% | RBC Capital | $81 → $84 | Maintains | Sector Perform | |||
11/15/2024 | -10.56% | Wolfe Research | → $110 | Initiates | → Outperform | |||
11/14/2024 | 1.63% | Citigroup | → $125 | Initiates | → Buy | |||
11/08/2024 | -29.26% | Morgan Stanley | $84 → $87 | Maintains | Equal-Weight | |||
11/08/2024 | — | Maxim Group | — | Downgrade | Buy → Hold | |||
11/08/2024 | -21.13% | Truist Securities | $83 → $97 | Maintains | Hold | |||
11/07/2024 | -14.63% | Oppenheimer | $95 → $105 | Maintains | Outperform | |||
11/07/2024 | -17.07% | BMO Capital | $94 → $102 | Maintains | Outperform | |||
11/07/2024 | -22.76% | Baird | $80 → $95 | Maintains | Neutral | |||
11/07/2024 | -14.63% | JP Morgan | $100 → $105 | Maintains | Overweight | |||
11/07/2024 | -34.14% | RBC Capital | $75 → $81 | Maintains | Sector Perform | |||
11/07/2024 | -31.7% | Goldman Sachs | $74 → $84 | Maintains | Neutral | |||
11/07/2024 | -34.95% | Cantor Fitzgerald | $70 → $80 | Maintains | Neutral | |||
11/07/2024 | -14.63% | Wells Fargo | $100 → $105 | Maintains | Overweight | |||
11/07/2024 | -22.76% | Barclays | $84 → $95 | Maintains | Equal-Weight | |||
11/07/2024 | -14.63% | Piper Sandler | $95 → $105 | Maintains | Overweight | |||
11/07/2024 | — | Needham | — | Reiterates | → Hold | |||
10/29/2024 | -39.02% | RBC Capital | $75 → $75 | Reiterates | Sector Perform → Sector Perform | |||
10/21/2024 | -21.94% | Leerink Partners | $74 → $96 | Upgrade | Market Perform → Outperform | |||
10/17/2024 | -23.57% | BMO Capital | $85 → $94 | Maintains | Outperform | |||
10/17/2024 | -14.63% | Bernstein | → $105 | Initiates | → Outperform | |||
10/09/2024 | -18.69% | JP Morgan | $95 → $100 | Maintains | Overweight | |||
10/07/2024 | -31.7% | Barclays | $76 → $84 | Maintains | Equal-Weight | |||
10/07/2024 | -18.69% | Wells Fargo | $78 → $100 | Upgrade | Equal-Weight → Overweight | |||
10/04/2024 | -39.02% | RBC Capital | $74 → $75 | Maintains | Sector Perform | |||
09/16/2024 | -43.08% | Cantor Fitzgerald | $70 → $70 | Reiterates | Neutral → Neutral | |||
09/11/2024 | -22.76% | Piper Sandler | $95 → $95 | Maintains | Overweight | |||
09/09/2024 | -43.08% | Cantor Fitzgerald | $70 → $70 | Reiterates | Neutral → Neutral | |||
09/04/2024 | -39.83% | RBC Capital | $72 → $74 | Maintains | Sector Perform | |||
08/15/2024 | -32.51% | Truist Securities | $82 → $83 | Maintains | Hold | |||
08/15/2024 | — | Needham | — | Reiterates | → Hold | |||
08/09/2024 | -41.46% | RBC Capital | $71 → $72 | Maintains | Sector Perform | |||
08/09/2024 | -43.08% | Cantor Fitzgerald | $70 → $70 | Reiterates | Neutral → Neutral | |||
08/09/2024 | -30.89% | BMO Capital | $80 → $85 | Maintains | Outperform | |||
07/22/2024 | -43.08% | Cantor Fitzgerald | $75 → $70 | Maintains | Neutral | |||
07/08/2024 | -24.38% | Raymond James | → $93 | Upgrade | Market Perform → Outperform | |||
07/01/2024 | -39.83% | RBC Capital | $74 → $74 | Reiterates | Sector Perform → Sector Perform | |||
06/20/2024 | -34.95% | Baird | $80 → $80 | Maintains | Neutral | |||
06/14/2024 | -39.83% | RBC Capital | $74 → $74 | Reiterates | Sector Perform → Sector Perform | |||
04/29/2024 | -38.21% | Barclays | $80 → $76 | Maintains | Equal-Weight | |||
04/26/2024 | -30.89% | TD Cowen | $90 → $85 | Maintains | Buy | |||
04/26/2024 | -36.58% | Morgan Stanley | $80 → $78 | Maintains | Equal-Weight | |||
04/26/2024 | -39.83% | RBC Capital | $76 → $74 | Maintains | Sector Perform | |||
04/26/2024 | — | Needham | — | Reiterates | → Hold | |||
04/24/2024 | -43.9% | HSBC | → $69 | Upgrade | Reduce → Hold | |||
04/19/2024 | -14.63% | Oppenheimer | $105 → $105 | Maintains | Outperform | |||
04/17/2024 | -39.02% | UBS | $81 → $75 | Maintains | Neutral | |||
03/04/2024 | -36.58% | Wells Fargo | $84 → $78 | Maintains | Equal-Weight | |||
02/22/2024 | -26.82% | Mizuho | $101 → $90 | Maintains | Buy | |||
02/22/2024 | -33.33% | Truist Securities | $91 → $82 | Downgrade | Buy → Hold | |||
02/14/2024 | -39.02% | RBC Capital | $76 → $75 | Maintains | Sector Perform | |||
02/12/2024 | -34.95% | Barclays | $85 → $80 | Maintains | Equal-Weight | |||
02/12/2024 | -14.63% | Oppenheimer | $115 → $105 | Maintains | Outperform | |||
02/07/2024 | -36.58% | Cantor Fitzgerald | $80 → $78 | Maintains | Neutral | |||
02/07/2024 | -38.21% | RBC Capital | $78 → $76 | Maintains | Sector Perform | |||
02/07/2024 | -31.7% | Wells Fargo | $90 → $84 | Maintains | Equal-Weight | |||
01/23/2024 | -30.89% | Barclays | $82 → $85 | Maintains | Equal-Weight | |||
11/14/2023 | -37.39% | RBC Capital | $78 → $77 | Maintains | Sector Perform | |||
11/09/2023 | -39.02% | Deutsche Bank | → $75 | Initiates | → Hold | |||
09/08/2023 | -22.76% | B of A Securities | $88 → $95 | Upgrade | Neutral → Buy | |||
09/06/2023 | -26.01% | Truist Securities | → $91 | Reiterates | Buy → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Gilead Sciences (GILD)?
El último precio objetivo de Gilead Sciences (NASDAQ:GILD) fue comunicado por Citigroup el octubre 8, 2025. La firma de analistas fijó un precio objetivo para $135.00 que espera GILD a rise dentro de 12 meses (un posible 9.77% upside). 58 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Gilead Sciences (GILD)?
La última calificación de analistas para Gilead Sciences (NASDAQ:GILD) fue proporcionada por Citigroup, y Gilead Sciences mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de Gilead Sciences (GILD)?
La última revisión al alza de Gilead Sciences Inc se produjo en agosto 8, 2025, cuando Truist Securities elevó su precio objetivo a $127. Truist Securities anteriormente tenía a hold para Gilead Sciences Inc.
¿Cuándo fue la última revisión a la baja de Gilead Sciences (GILD)?
La última revisión a la baja de Gilead Sciences Inc se produjo en noviembre 8, 2024, cuando Maxim Group cambió su precio objetivo de N/A a N/A para Gilead Sciences Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Gilead Sciences (GILD)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Gilead Sciences, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Gilead Sciences se registró el octubre 8, 2025, por lo que la próxima calificación estará disponible en torno al octubre 8, 2026.
¿Es correcta la calificación de los analistas sobre Gilead Sciences (GILD)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Gilead Sciences (GILD) fue un mantuvo con un precio objetivo de $125.00 a $135.00. El precio actual al que cotiza Gilead Sciences (GILD) es de $122.99, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.